Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • ASCI Milestone Awards
    • Video Abstracts
    • Conversations with Giants in Medicine
  • Reviews
    • View all reviews ...
    • Clinical innovation and scientific progress in GLP-1 medicine (Nov 2025)
    • Pancreatic Cancer (Jul 2025)
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • ASCI Milestone Awards
  • Video Abstracts
  • Conversations with Giants in Medicine
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
β3-adrenoceptor deficiency blocks nitric oxide–dependent inhibition of myocardial contractility
Paul Varghese, Robert W. Harrison, Robert A. Lofthouse, Dimitrios Georgakopoulos, Dan E. Berkowitz, Joshua M. Hare
Paul Varghese, Robert W. Harrison, Robert A. Lofthouse, Dimitrios Georgakopoulos, Dan E. Berkowitz, Joshua M. Hare
View: Text | PDF
Article

β3-adrenoceptor deficiency blocks nitric oxide–dependent inhibition of myocardial contractility

  • Text
  • PDF
Abstract

The cardiac β-adrenergic pathway potently stimulates myocardial performance, thereby providing a mechanism for myocardial contractile reserve. β-Adrenergic activation also increases cardiac nitric oxide (NO) production, which attenuates positive inotropy, suggesting a possible negative feedback mechanism. Recently, in vitro studies suggest that stimulation of the β3-adrenoceptor results in a negative inotropic effect through NO signaling. In this study, using mice with homozygous β3-adrenoceptor deletion mutations, we tested the hypothesis that the β3-adrenoceptor is responsible for β-adrenergic activation of NO. Although resting indices of myocardial contraction were similar, β-adrenergic–stimulated inotropy was increased in β3–/– mice, and similar hyper-responsiveness was seen in mice lacking endothelial NO synthase (NOS3). NOS inhibition augmented isoproterenol-stimulated inotropy in wild-type (WT), but not in β3–/– mice. Moreover, isoproterenol increased myocardial cGMP in WT, but not β3–/–, mice. NOS3 protein abundance was not changed in β3–/– mice, and cardiac β3-adrenoceptor mRNA was detected in both NOS3–/– and WT mice. These findings indicate that the β3-adrenergic subtype participates in NO-mediated negative feedback over β-adrenergic stimulation.

Authors

Paul Varghese, Robert W. Harrison, Robert A. Lofthouse, Dimitrios Georgakopoulos, Dan E. Berkowitz, Joshua M. Hare

×

Figure 4

Options: View larger image (or click on image) Download as PowerPoint
Abundance of NOS3 protein and β3–/– mRNA in myocardium. (a) Western blot...
Abundance of NOS3 protein and β3–/– mRNA in myocardium. (a) Western blot of NOS3 from mouse heart tissue. Equal amounts of protein extracts were resolved on agarose gels, transferred to nitrocellulose, and exposed to anti-NOS3 Ab or anti–p-38 Ab. The FVB and β3–/– mice had similar NOS3 abundance relative to p-38 MAP kinase, and NOS3 was absent in the NOS3–/– mice. (b) Representative ethidium-stained agarose gel demonstrating expression of β3-adrenoceptor mRNA in different mice strains: mRNA is expressed in both heart (H) and epididymal fat (F) of NOS3–/– and FVB control mice, but not β3–/– mice. Little or no PCR product is amplified in reactions lacking reverse transcriptase (H-), confirming minimal genomic contamination of mRNA. (c) Autoradiograph of RNase protection assay confirming the expression of β3-adrenoceptor in the myocardium of FVB and NOS3–/– mouse hearts. β3AR P, β3-adrenoceptor probe; β3AR PF, β3-adrenoceptor–protected fragment.

Copyright © 2026 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts